Show simple item record

dc.contributor.authorUceda-Castro, R.
dc.contributor.authorMargarido, A. S.
dc.contributor.authorCornet, L.
dc.contributor.authorVegna, S.
dc.contributor.authorHahn, K.
dc.contributor.authorSong, J. Y.
dc.contributor.authorPutavet, D. A.
dc.contributor.authorvan Geldorp, M.
dc.contributor.authorÇitirikkaya, C. H.
dc.contributor.authorde Keizer, P. L. J.
dc.contributor.authorTer Beek, L. C.
dc.contributor.authorBorst, Gerben R
dc.contributor.authorAkkari, L.
dc.contributor.authorvan Tellingen, O.
dc.contributor.authorBroekman, M. L. D.
dc.contributor.authorVennin, C.
dc.contributor.authorvan Rheenen, J.
dc.date.accessioned2023-01-16T14:12:42Z
dc.date.available2023-01-16T14:12:42Z
dc.date.issued2022en
dc.identifier.citationUceda-Castro R, Margarido AS, Cornet L, Vegna S, Hahn K, Song JY, et al. Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis. Cell reports Medicine. 2022 Nov 15;3(11):100821. PubMed PMID: 36384097. Pubmed Central PMCID: PMC9729880. Epub 2022/11/18. eng.en
dc.identifier.pmid36384097en
dc.identifier.doi10.1016/j.xcrm.2022.100821en
dc.identifier.urihttp://hdl.handle.net/10541/625852
dc.description.abstractAn increasing number of breast cancer patients develop brain metastases (BM). Standard-of-care treatments are largely inefficient, and breast cancer brain metastasis (BCBM) patients are considered untreatable. Immunotherapies are not successfully employed in BCBM, in part because breast cancer is a "cold" tumor and also because the brain tissue has a unique immune landscape. Here, we generate and characterize immunocompetent models of BCBM derived from PyMT and Neu mammary tumors to test how harnessing the pro-senescence properties of doxorubicin can be used to prime the specific immune BCBM microenvironment. We reveal that BCBM senescent cells, induced by doxorubicin, trigger the recruitment of PD1-expressing T cells to the brain. Importantly, we demonstrate that induction of senescence with doxorubicin improves the efficacy of immunotherapy with anti-PD1 in BCBM in a CD8 T cell-dependent manner, thereby providing an optimized strategy to introduce immune-based treatments in this lethal disease. In addition, our BCBM models can be used for pre-clinical testing of other therapeutic strategies in the future.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.xcrm.2022.100821en
dc.titleRe-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasisen
dc.typeArticleen
dc.contributor.departmentDivision of Molecular Pathology, Oncode Institute, The Netherlands Cancer Institute, 1066 Amsterdam, North Holland, the Netherlandsen
dc.identifier.journalCell Reports. Medicineen
dc.description.noteen]
refterms.dateFOA2023-01-17T09:27:17Z


Files in this item

Thumbnail
Name:
36384097.pdf
Size:
7.862Mb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record